# Cytheris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytheris

- Industry: Pharmaceuticals
- Headquarters: Issy-les-Moulineaux, France
- Website: www.cytheris.com
- Total disclosed funding: $56M
- Latest round: Series D (Jun 7, 2010)
- Investors on record: 7

## About

Founded in 1999, Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

## Funding rounds

- Series D, Jun 7, 2010, $15M — CDPQ, CDC Entreprises, Omnes Capital, Bioam Gestion, Forbion
- Series B, Oct 25, 2006, $31M — Ardian, CDPQ, CDC Entreprises, Omnes Capital, T2C2, Bioam Gestion, Forbion
- Series B, Jul 1, 2002, $10M — Ardian, CDPQ, T2C2, Bioam Gestion

## Investors

- Ardian (https://capitalatlas.ai/funds/ardian) — Series B
- CDPQ — Series B, Series D
- T2C2 (https://capitalatlas.ai/funds/t2c2) — Series B
- Bioam Gestion (https://capitalatlas.ai/funds/bioam-gestion) — Series B, Series D
- CDC Entreprises — Series B, Series D
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series B, Series D
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series D